Positions

Overview

  • Dr. Kennedy is certified by the American Board of Colon and Rectal Surgery and by the American Board of Surgery. In addition, he is a Fellow of the American College of Surgeons and a Fellow of the American Society of Colon and Rectal Surgery. Kennedy’s main interest is in laparoscopic approaches to complex colorectal disease. He has experience with all advanced laparoscopic and minimally invasive approaches including single-incision laparoscopy and robotic surgery. His clinical areas of expertise include colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease.

    Dr. Kennedy was born and raised in Montana and is a graduate of the University of Washington School of Medicine in Seattle. He earned his doctorate in cancer biology at the University of Wisconsin School of Medicine and Public Health, where he also completed his general surgery residency in 2006. Dr. Kennedy then completed his colon and rectal surgery fellowship at the Mayo Clinic in Rochester, Minn., in 2007.

    Dr. Kennedy’s research efforts are focused on chemoprevention of colon and rectal cancer. His funded laboratory uses genetic models to better understand how chemicals prevent tumor formation and what genetic pathways are responsible for their effects. The ultimate goal is to identify targeted agents that are better tolerated by patients in hopes of preventing colon and rectal cancer.
  • Selected Publications

    Book

    Year Title Altmetric
    2003 Virus-based vectors for gene expression in mammalian cells: Epstein-Barr virus.  Ed. 38.  2003

    Chapter

    Year Title Altmetric
    2016 Anal fissure.  497-503. 2016
    2016 Cryptoglandular disease.  463-482. 2016
    2016 Hemorrhoids.  505-519. 2016
    2016 Pilonidal disease.  483-496. 2016
    2015 Palliative options in patients with stage 4 rectal cancer.  367-384. 2015
    2010 Cryptoglandular disease.  195-206. 2010
    2010 Hemorrhoids.  217-224. 2010
    2010 Lateral internal sphincterotomy.  189-193. 2010
    2010 Pilonidal operations.  207-215. 2010

    Research Overview

  • colon cancer, rectal cancer, anal cancer, inflammatory bowel disease, benign conditions of colon, rectum and anus, endoscopic treatment of colonic disease, chemoprevention
  • Principal Investigator On

  • PREVENT Cancer Preclinical and Drug Development Program  awarded by NIH - National Institutes of Health/DHHS
  • Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers  awarded by NIH - National Institutes of Health/DHHS
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by DAVOL (A.C.R. BARD INC.)
  • Research Training Program in Surgical Oncology  awarded by National Cancer Institute/NIH/DHHS
  • Surgical Oncology Research Training Program  awarded by National Cancer Institute/NIH/DHHS
  • T001 HHSN2610009 (old 000509388-T008) Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluating Whether a Concurrent Retinoid X Receptor Agonist Can Enhance the Efficacy of HER2-IGFPB2-IGFLR Vaccine in Eliminating Existing Ductal Carcinoma in Situ and Preventing Progression of Invasive Breast Cancer  awarded by NIH - National Institutes of Health/DHHS
  • T002 HHSN261201500036I-75N91018F00011 (Old 000509388-T011) Preclinical Efficacy and Intermediate Endpoint Biomarkers - Further Development of Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer  awarded by NIH - National Institutes of Health/DHHS
  • T005 HHSN26100008 (Old 000509388-T009)TORFP 2018-E03 Prevention of Urinary Bladder Cancer with Two "Clinically-Ready" Agents (Everolimus and Naproxen) when Administered in Combination  awarded by NIH - National Institutes of Health/DHHS
  • T006 HHSN26100010 (Old 509388 - T010) TORFP 2018-E07 Preclinical Development of a Chemopreventive Agent, 4-Methylumbelliferone (4-MU)  awarded by NIH - National Institutes of Health/DHHS
  • TORFP 2019-E03 75N91019D00019 75N91019F00130 Evaluation of Two Different Classes of Compounds (STAT3 Inhibitors and SERMs) for Prevention  awarded by NIH - National Institutes of Health/DHHS
  • TORFP 2019-E04 75N91010D00019 75N91019F00132 Colorectal Cancer Prevention by Novel EPA Analogue TP-252 and Naproxen in FAP and Lynch Syndrone Models  awarded by NIH - National Institutes of Health/DHHS
  • TORFP 2019-E06 75N91019D00019 75N91019F00131 Further Development of Colovac, a Multi-Antigen Multi-Peptide Vaccine, for Colon Cancer Prevention  awarded by NIH - National Institutes of Health/DHHS
  • The Role of Aryl Hyrocarbon Receptor in Colon Tumorigenesis  awarded by National Institute of Environmental Health Sciences/NIH/DHHS
  • Education And Training

  • University of Wisconsin Surgery, Chief Resident
  • University of Wisconsin-Madison Oncology, Postdoctoral Research
  • Mayo Clinic, Rochester Colon and Rectal Surgery, Residency
  • University of Wisconsin, Residency
  • University of Wisconsin-Madison Surgery, Residency
  • Doctor of Philosophy in Oncology and Cancer Biology, University of Wisconsin System : Madison 2003
  • Doctor of Medicine, University of Washington 1996
  • Bachelor of Science or Mathematics in Biomedical Sciences, Montana State University System : Bozeman 1992
  • Full Name

  • Gregory Kennedy